Jiekang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiekang Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Mei Wan
Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
4 shared publications - Xu Cao
Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, USA
2 shared publications - Zhiliang Wei
Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins University School of Medicine Baltimore Maryland USA
2 shared publications - Adnan Bibic
Department of Medical Radiation Physics, Lund University, Lund, Sweden
1 shared publication - Ching-Lien Fang
Department of Orthopaedic Surgery
1 shared publication - Guanqiao Liu
Guangdong Institute of Orthopaedics & Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
The bone-cerebrovascular axis: effects of bone aging on neurovascular dysfunction and neurodegeneration
Beyond serving as a structural organ, the skeleton undergoes continuous remodeling and functions as an endocrine organ by secreting bioactive factors that regulate the physiology of distant tissues. Indeed, the concept of a “bone-vascular axis” has long been recognized, supported by epidemiological evidence linking osteoporosis and low bone mass to increased cardiovascular morbidity and mortality. Emerging findings now extend this paradigm to the brain, suggesting that bone- and bone marrow–derived signals influence cerebrovascular structure, function, and aging. Given that cerebrovascular dysfunction is a central driver of age-related cognitive decline, dementia, and neurodegenerative diseases, understanding this “bone-cerebrovascular axis” may offer novel opportunities for prevention and intervention. Here, we outline the cellular and molecular mechanisms underlying age-associated neurovascular impairment and summarize the biology of major bone and bone marrow cell populations, with emphasis on age-related alterations in their secretome. A central focus of this Review is the emerging evidence that age-related skeletal alterations exert systemic effects on the cerebrovasculature, highlighting how bone- and bone marrow–derived factors shape neurovascular health and pathology, which may subsequently contribute to CNS aging and neurodegeneration. A deeper understanding of these systemic interactions reframes brain aging within a whole-body context and may uncover innovative biomarkers and therapeutic strategies to mitigate neurodegeneration and other age-associated disorders.
- 2 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Open AccessThe bone-cerebrovascular axis: effects of bone aging on neurovascular dysfunction and neurodegeneration
Beyond serving as a structural organ, the skeleton undergoes continuous remodeling and functions as an endocrine organ by secreting bioactive factors that regulate the physiology of distant tissues. Indeed, the concept of a “bone-vascular axis” has long been recognized, supported by epidemiological evidence linking osteoporosis and low bone mass to increased cardiovascular morbidity and mortality. Emerging findings now extend this paradigm to the brain, suggesting that bone- and bone marrow–derived signals influence cerebrovascular structure, function, and aging. Given that cerebrovascular dysfunction is a central driver of age-related cognitive decline, dementia, and neurodegenerative diseases, understanding this “bone-cerebrovascular axis” may offer novel opportunities for prevention and intervention. Here, we outline the cellular and molecular mechanisms underlying age-associated neurovascular impairment and summarize the biology of major bone and bone marrow cell populations, with emphasis on age-related alterations in their secretome. A central focus of this Review is the emerging evidence that age-related skeletal alterations exert systemic effects on the cerebrovasculature, highlighting how bone- and bone marrow–derived factors shape neurovascular health and pathology, which may subsequently contribute to CNS aging and neurodegeneration. A deeper understanding of these systemic interactions reframes brain aging within a whole-body context and may uncover innovative biomarkers and therapeutic strategies to mitigate neurodegeneration and other age-associated disorders.
- Open Access
Vascular Microbleeds Without Brain Atrophy: A Microvascular Signature of Mid-Stage 5xFAD Pathology
Cerebral microbleeds are increasingly recognized as a downstream manifestation of vascular injury in Alzheimer disease (AD), arising secondary to cerebral amyloid angiopathy (CAA). Here, we examined the pathological specificity of microbleeds by comparing an amyloidosis mouse model (5xFAD) with a small-vessel disease (SVD) model characterized by vascular smooth-muscle cell loss. In vivo multimodal MRI, including gradient-echo, spin-echo, and diffusion-weighted imaging, was complemented by ex vivo high-resolution anatomical scans for validation. Both in vivo and ex vivo gradient-echo MRI consistently revealed hippocampal microbleeds in the 5xFAD model without macroscopic atrophy or ventricular enlargement, whereas no microbleeds or blood-brain barrier disruption were detected in the SVD model. Diffusion-weighted MRI further showed region-specific alterations in apparent diffusion coefficient within the midbrain of 5xFAD mice, but not in other regions or in the SVD cohort. These findings indicate that microbleeds are a pathology-specific marker of amyloid-related vascular injury rather than a general indicator of small-vessel impairment. The combined imaging evidence underscores the potential of microbleeds as a disease-specific biomarker for detecting amyloid-driven vascular fragility and refining diagnostic and therapeutic strategies for AD.
Open AccessVascular Microbleeds Without Brain Atrophy: A Microvascular Signature of Mid-Stage 5xFAD Pathology
Cerebral microbleeds are increasingly recognized as a downstream manifestation of vascular injury in Alzheimer disease (AD), arising secondary to cerebral amyloid angiopathy (CAA). Here, we examined the pathological specificity of microbleeds by comparing an amyloidosis mouse model (5xFAD) with a small-vessel disease (SVD) model characterized by vascular smooth-muscle cell loss. In vivo multimodal MRI, including gradient-echo, spin-echo, and diffusion-weighted imaging, was complemented by ex vivo high-resolution anatomical scans for validation. Both in vivo and ex vivo gradient-echo MRI consistently revealed hippocampal microbleeds in the 5xFAD model without macroscopic atrophy or ventricular enlargement, whereas no microbleeds or blood-brain barrier disruption were detected in the SVD model. Diffusion-weighted MRI further showed region-specific alterations in apparent diffusion coefficient within the midbrain of 5xFAD mice, but not in other regions or in the SVD cohort. These findings indicate that microbleeds are a pathology-specific marker of amyloid-related vascular injury rather than a general indicator of small-vessel impairment. The combined imaging evidence underscores the potential of microbleeds as a disease-specific biomarker for detecting amyloid-driven vascular fragility and refining diagnostic and therapeutic strategies for AD.
- Open Access
- 2 April 2025
- Published by Scilight Press Pty Ltd in Health and Metabolism
- Vol. 2 (2) , 2
Vascular and Metabolic Responses to Elevated Circulating PDGF-BB in Mice: A Multiparametric MRI Study
Article Vascular and Metabolic Responses to Elevated Circulating PDGF-BB in Mice: A Multiparametric MRI Study Xiuli Yang 1,†, Jiekang Wang 2,3,†, Yuguo Li 1,4, Mei Wan 2,3,*, Zhiliang Wei 1,4,* 1 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 2 Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 3 Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 4 F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Research Institute, Baltimore, MD 21205, USA * Correspondence: mwan4@jhmi.edu (M.W.); zhiliang.wei@jhu.edu (Z.W.) † These authors contributed equally to this work. Received: 20 November 2024; Revised: 20 December 2024; Accepted: 22 January 2025; Published: 11 February 2025 Elevated circulating platelet-derived growth factor-BB (PDGF-BB) has been implicated in the development of various aged-related pathologies and is recognized as a potential pro-aging factor. Although numerous studies have explored the pathological roles of the PDGF-BB/PDGFRβ signaling pathway, few investigations have dissected its function in neurofunctional responses to elevated circulating PDGF-BB, primarily because in-vivo measurements are generally required to assess neurofunction. To address this knowledge gap, we characterized the vascular and metabolic responses to elevated circulating PDGF-BB in vivo using multiparametric non-invasive non-contrast MRI techniques in a conditional Pdgfb transgenic mouse model (PdgfbcTG) at 6 months of age. Results indicated that PdgfbcTG mice exhibited decreased cerebral blood flow (p = 0.025), elevated oxygen extraction (p = 0.002), and increased metabolic rate of oxygen (p = 0.035), mirroring the changes observed in human aging. The rate of change in vascular and metabolic measurements in the model mice was significantly higher (≥200.3%) compared to that of naturally aged mice. This study provides neurofunctional evidence that elevated circulating PDGF-BB accelerates neurovascular aging.
- 2 April 2025
- Published by Scilight Press Pty Ltd in Health and Metabolism
- Vol. 2 (2) , 2
Open AccessVascular and Metabolic Responses to Elevated Circulating PDGF-BB in Mice: A Multiparametric MRI Study
Article Vascular and Metabolic Responses to Elevated Circulating PDGF-BB in Mice: A Multiparametric MRI Study Xiuli Yang 1,†, Jiekang Wang 2,3,†, Yuguo Li 1,4, Mei Wan 2,3,*, Zhiliang Wei 1,4,* 1 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 2 Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 3 Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 4 F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Research Institute, Baltimore, MD 21205, USA * Correspondence: mwan4@jhmi.edu (M.W.); zhiliang.wei@jhu.edu (Z.W.) † These authors contributed equally to this work. Received: 20 November 2024; Revised: 20 December 2024; Accepted: 22 January 2025; Published: 11 February 2025 Elevated circulating platelet-derived growth factor-BB (PDGF-BB) has been implicated in the development of various aged-related pathologies and is recognized as a potential pro-aging factor. Although numerous studies have explored the pathological roles of the PDGF-BB/PDGFRβ signaling pathway, few investigations have dissected its function in neurofunctional responses to elevated circulating PDGF-BB, primarily because in-vivo measurements are generally required to assess neurofunction. To address this knowledge gap, we characterized the vascular and metabolic responses to elevated circulating PDGF-BB in vivo using multiparametric non-invasive non-contrast MRI techniques in a conditional Pdgfb transgenic mouse model (PdgfbcTG) at 6 months of age. Results indicated that PdgfbcTG mice exhibited decreased cerebral blood flow (p = 0.025), elevated oxygen extraction (p = 0.002), and increased metabolic rate of oxygen (p = 0.035), mirroring the changes observed in human aging. The rate of change in vascular and metabolic measurements in the model mice was significantly higher (≥200.3%) compared to that of naturally aged mice. This study provides neurofunctional evidence that elevated circulating PDGF-BB accelerates neurovascular aging.
- Open Access
- 9 January 2025
- Vol. 20 (Suppl 8)
Bone‐Derived PDGF‐BB Accelerates Aβ Plaque Formation and Cerebrovascular Impairment
Blood exchange experiments in heterochronic parabionts or heterochronic plasma transfer have revealed that age‐associated changes in blood composition contribute to neurogenesis and cognitive impairment in the elderly, and multiple blood‐born pro‐aging factors have been identified as causal factors to accelerate age‐dependent brain changes. We previously demonstrate that PDGF‐BB secreted by pre‐osteoclasts in bone mediates cerebrovascular impairment during aging, but the bone‐derived PDGF‐BB in Alzheimer’s disease (AD) progression is still uncertain. MCI patients and two transgenic AD mouse models, App‐ps1 and 5XFAD, were used to evaluated PDGF‐BB level by ELISA measurement. Moreover, heterochronic parabiosis experiments were conducted using our established “PdgfbcTG ” mice, in which Pdgfb was overexpressed in pre‐osteoclasts, resulting the circulating PDGF‐BB concentration is elevated about 3‐fold relative to their WT littermates. Parabiosis surgery was performed to anastomose 10‐month‐old PdgfbcTG mice with 10‐month‐old App‐ps1 mice. As control mouse pairs, age‐matched wild type mice were anastomosed with App‐ps1 mice. Six weeks after the parabiosis surgery, the mice were sacrificed. Serum was collected, and the brain tissue were prepared for immunofluorescence staining. Comparing with MCI and healthy people, approximately 3‐fold increase of circulating PDGF‐BB. Both APP‐ps1 and 5XFAD mice displayed approximately 2‐fold increase of circulating PDGF‐BB concentration compared to their WT littermates. In parabiosis experiments, the number and area of Aβ plaques in cortex region were greatly higher in the APP‐PS1 parabionts that were paired with PdgfbcTG mice compared to those paired with WT mice, as indicated by ThioflavinS staining and 6E10+ immunofluorescence staining. The cortex of APP‐ps1 parabionts paired with PdgfbcTG mice showed a significant rise in GFAP+ astrocytes compared to those paired with WT mice, indicating heightened neuroinflammation. APP‐ps1 parabionts paired with PdgfbcTG mice also showed altered brain capillaries and greater BBB leakage in brain tissue than those paired with WT mice. Our findings strongly suggested that increased circulating PDGF‐BB is sufficient to accelerate AD pathogenesis. Further examining the role of PDGF‐BB in exacerbating/ accelerating brain aging and AD progression may lead to the development of circulating PDGF‐BB as a new biomarker for brain degeneration.
- 9 January 2025
- Vol. 20 (Suppl 8)
Open AccessBone‐Derived PDGF‐BB Accelerates Aβ Plaque Formation and Cerebrovascular Impairment
Blood exchange experiments in heterochronic parabionts or heterochronic plasma transfer have revealed that age‐associated changes in blood composition contribute to neurogenesis and cognitive impairment in the elderly, and multiple blood‐born pro‐aging factors have been identified as causal factors to accelerate age‐dependent brain changes. We previously demonstrate that PDGF‐BB secreted by pre‐osteoclasts in bone mediates cerebrovascular impairment during aging, but the bone‐derived PDGF‐BB in Alzheimer’s disease (AD) progression is still uncertain. MCI patients and two transgenic AD mouse models, App‐ps1 and 5XFAD, were used to evaluated PDGF‐BB level by ELISA measurement. Moreover, heterochronic parabiosis experiments were conducted using our established “PdgfbcTG ” mice, in which Pdgfb was overexpressed in pre‐osteoclasts, resulting the circulating PDGF‐BB concentration is elevated about 3‐fold relative to their WT littermates. Parabiosis surgery was performed to anastomose 10‐month‐old PdgfbcTG mice with 10‐month‐old App‐ps1 mice. As control mouse pairs, age‐matched wild type mice were anastomosed with App‐ps1 mice. Six weeks after the parabiosis surgery, the mice were sacrificed. Serum was collected, and the brain tissue were prepared for immunofluorescence staining. Comparing with MCI and healthy people, approximately 3‐fold increase of circulating PDGF‐BB. Both APP‐ps1 and 5XFAD mice displayed approximately 2‐fold increase of circulating PDGF‐BB concentration compared to their WT littermates. In parabiosis experiments, the number and area of Aβ plaques in cortex region were greatly higher in the APP‐PS1 parabionts that were paired with PdgfbcTG mice compared to those paired with WT mice, as indicated by ThioflavinS staining and 6E10+ immunofluorescence staining. The cortex of APP‐ps1 parabionts paired with PdgfbcTG mice showed a significant rise in GFAP+ astrocytes compared to those paired with WT mice, indicating heightened neuroinflammation. APP‐ps1 parabionts paired with PdgfbcTG mice also showed altered brain capillaries and greater BBB leakage in brain tissue than those paired with WT mice. Our findings strongly suggested that increased circulating PDGF‐BB is sufficient to accelerate AD pathogenesis. Further examining the role of PDGF‐BB in exacerbating/ accelerating brain aging and AD progression may lead to the development of circulating PDGF‐BB as a new biomarker for brain degeneration.
- Open Access
- 1 December 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (23)
Bone-derived PDGF-BB drives brain vascular calcification in male mice
Brain vascular calcification is a prevalent age-related condition often accompanying neurodegenerative and neuroinflammatory diseases. The pathogenesis of large-vessel calcifications in peripheral tissue is well studied, but microvascular calcification in the brain remains poorly understood. Here, we report that elevated platelet-derived growth factor BB (PDGF-BB) from bone preosteoclasts contributed to cerebrovascular calcification in male mice. Aged male mice had higher serum PDGF-BB levels and a higher incidence of brain calcification compared with young mice, mainly in the thalamus. Transgenic mice with preosteoclast-specific Pdgfb overexpression exhibited elevated serum PDGF-BB levels and recapitulated age-associated thalamic calcification. Conversely, mice with preosteoclast-specific Pdgfb deletion displayed diminished age-associated thalamic calcification. In an ex vivo cerebral microvascular culture system, PDGF-BB dose-dependently promoted vascular calcification. Analysis of osteogenic gene array and single-cell RNA-Seq (scRNA-Seq) revealed that PDGF-BB upregulated multiple osteogenic differentiation genes and the phosphate transporter Slc20a1 in cerebral microvessels. Mechanistically, PDGF-BB stimulated the phosphorylation of its receptor PDGFRβ (p-PDGFRβ) and ERK (p-ERK), leading to the activation of RUNX2. This activation, in turn, induced the transcription of osteoblast differentiation genes in PCs and upregulated Slc20a1 in astrocytes. Thus, bone-derived PDGF-BB induced brain vascular calcification by activating the p-PDGFRβ/p-ERK/RUNX2 signaling cascade in cerebrovascular cells.
- 1 December 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (23)
Open AccessBone-derived PDGF-BB drives brain vascular calcification in male mice
Brain vascular calcification is a prevalent age-related condition often accompanying neurodegenerative and neuroinflammatory diseases. The pathogenesis of large-vessel calcifications in peripheral tissue is well studied, but microvascular calcification in the brain remains poorly understood. Here, we report that elevated platelet-derived growth factor BB (PDGF-BB) from bone preosteoclasts contributed to cerebrovascular calcification in male mice. Aged male mice had higher serum PDGF-BB levels and a higher incidence of brain calcification compared with young mice, mainly in the thalamus. Transgenic mice with preosteoclast-specific Pdgfb overexpression exhibited elevated serum PDGF-BB levels and recapitulated age-associated thalamic calcification. Conversely, mice with preosteoclast-specific Pdgfb deletion displayed diminished age-associated thalamic calcification. In an ex vivo cerebral microvascular culture system, PDGF-BB dose-dependently promoted vascular calcification. Analysis of osteogenic gene array and single-cell RNA-Seq (scRNA-Seq) revealed that PDGF-BB upregulated multiple osteogenic differentiation genes and the phosphate transporter Slc20a1 in cerebral microvessels. Mechanistically, PDGF-BB stimulated the phosphorylation of its receptor PDGFRβ (p-PDGFRβ) and ERK (p-ERK), leading to the activation of RUNX2. This activation, in turn, induced the transcription of osteoblast differentiation genes in PCs and upregulated Slc20a1 in astrocytes. Thus, bone-derived PDGF-BB induced brain vascular calcification by activating the p-PDGFRβ/p-ERK/RUNX2 signaling cascade in cerebrovascular cells.